Allarity Therapeutics, Inc. ALLR 深 滬
已收盤 08-08 16:00:00 美东时间
0.97
-0.016
-1.66%
華盛通- 最 高1.01
- 今 開0.9815
- 成交量 28.96万股
- 最 低 0.96
- 昨 收 0.9864
- 總市值 1462.72万
- 52周最高 6.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.6138
- 委 比 -79.53%
- 總股本 1507.96万
- 歷史最高 15288000.00
- 量 比 1.14
- 振 幅 5.07%
- 歷史最低 0.6138
- 每 手 1
- 風險率 1.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Ascendiant Capital Initiates Coverage On Allarity Therapeutics with Buy Rating, Announces Price Target of $9
Ascendiant Capital analyst Edward Woo initiates coverage on Allarity Therapeutics (NASDAQ:ALLR) with a Buy rating and announces Price Target of $9.
07-28 17:39
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
Allarity Therapeutics has signed a commercial agreement with a EU-based biotech company, granting a global license to its DRP® algorithms for breast cancer and laboratory services. The partnership supports precision oncology solutions and secures lab service commitments. CEO Thomas Jensen highlighted DRP's broad applicability and the lab's expertise. DRP uses gene expression profiling to predict tumor responses, potentially improving patient outc...
07-15 12:00
Jeffrey S. Ervin Appointed as Allarity’s New CFO
An announcement from Allarity Therapeutics ( ($ALLR) ) is now available. On Jun...
07-07 20:58
Allarity Therapeutics appoints Jeff Ervin as CFO
Allarity Therapeutics (NASDAQ:ALLR) announced on Monday the appointment of Jeff Ervin as the company’s new chief financial officer (CFO). Ervin succeeds Alexander Epshinsky, who will remain engaged w...
07-07 20:08
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
Allarity Therapeutics appointed Jeff Ervin as its new Chief Financial Officer, succeeding Alexander Epshinsky. Ervin brings over 20 years of leadership experience in healthcare and biotech, including roles at DayDayCook and IMAC Holdings. He holds an MBA from Vanderbilt University and currently serves on the board of Cingulate Inc. Ervin's expertise in public company management and financial strategy is expected to support Allarity's clinical dev...
07-07 12:00
Allarity Therapeutics Advances Phase 2 Stenoparib Trial
Allarity Therapeutics ( ($ALLR) ) has provided an announcement. On June 27, 202...
07-01 02:43
Allarity Therapeutics Files Form RW, Has Determined Not To Pursue The Public Offering To Which The Registration Statement Relates; The Registration Statement Has Not Been Declared Effective By The Commission And No Securities Have Been Issued Or Sold Under The Registration Statement.
https://www.sec.gov/Archives/edgar/data/1860657/000121390025056913/ea024655701-rw_allaritythera.htm
06-24 20:18
Allarity Therapeutics Announces Changes to Board of Directors
Allarity Therapeutics announced the appointment of Jesper Høiland to its Board of Directors, replacing Joseph Vazzano, who is resigning effective June 30, 2025. Høiland, a seasoned pharmaceutical industry leader with over 30 years of experience, brings extensive expertise in commercialization and executive leadership. His previous roles include President and EVP of Novo Nordisk's U.S. operations, President and CEO of Radius Health, and Global Com...
06-11 20:05
Allarity Therapeutics Partners with Indiana Biosciences
Allarity Therapeutics ( ($ALLR) ) just unveiled an update. On June 4, 2025, All...
06-05 20:28
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
Allarity Therapeutics collaborates with Indiana Biosciences Research Institute (IBRI) to deepen understanding of stenoparib's dual PARP and WNT pathway inhibition机制, enhancing its potential as a personalized cancer treatment. Stenoparib's unique dual activity addresses chemotherapy-resistant cancers and may expand therapeutic opportunities. The collaboration supports clinical development, regulatory efforts, and optimization of the DRP® patient s...
06-04 12:00
